Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
7.32
+0.63 (9.42%)
At close: Feb 6, 2026, 4:00 PM EST
7.37
+0.05 (0.68%)
After-hours: Feb 6, 2026, 4:10 PM EST
IMDX Employees
As of December 31, 2024, Insight Molecular Diagnostics had 49 total employees, including 46 full-time and 3 part-time employees. The number of employees increased by 3 or 6.52% compared to the previous year.
Employees
49
Change (1Y)
3
Growth (1Y)
6.52%
Revenue / Employee
$89,837
Profits / Employee
-$1,240,367
Market Cap
209.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 49 | 3 | 6.52% | 46 | 3 |
| Dec 31, 2023 | 46 | -30 | -39.47% | 43 | 3 |
| Dec 31, 2022 | 76 | -39 | -33.91% | 75 | 1 |
| Dec 31, 2021 | 115 | 64 | 125.49% | 110 | 5 |
| Dec 31, 2020 | 51 | 18 | 54.55% | 51 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| OPKO Health | 2,997 |
| Myriad Genetics | 2,700 |
| Fulgent Genetics | 1,313 |
| Castle Biosciences | 823 |
| Burning Rock Biotech | 674 |
| FONAR | 535 |
| MDxHealth | 312 |
| Prenetics Global | 285 |
IMDX News
- 26 days ago - IMDX Supports AST and ASHI STAR Working Group's Call for Decentralized Transplant Monitoring - GlobeNewsWire
- 4 weeks ago - iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation - GlobeNewsWire
- 4 weeks ago - iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch - GlobeNewsWire
- 4 weeks ago - iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion - GlobeNewsWire
- 3 months ago - Insight Molecular Diagnostics Inc. (IMDX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch - GlobeNewsWire
- 3 months ago - iMDx to Release Third Quarter 2025 Results on November 10 and Attend Stephens Annual Investment Conference the Following Week - GlobeNewsWire
- 4 months ago - iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewsWire